GlassScriptPhysician profile
Tiffany M Brady
NPI 1073249272
$3,949.39
in general payments reported to CMS, 2019-2025
26 companies · $2,334 in 2025
The $2,334 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $345 · 2024: $1,270 · 2025: $2,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,949.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $476.33 | 2024-2025 | Auvelity |
| Abbvie INC. | $462.60 | 2023-2025 | |
| Lundbeck LLC | $328.85 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $318.64 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Gilead Sciences, INC. | $311.43 | 2024-2025 | Biktarvy |
| Alkermes, INC. | $290.93 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $286.21 | 2023-2025 | Fanapt, Hetlioz |
| Viiv Healthcare Company | $283.27 | 2025 | Dovato, Cabenuva, Apretude |
| Neurocrine Biosciences, INC. | $210.14 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $201.94 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $129.40 | 2024-2025 | Pifeltro, Delstrigo, Capvaxive |
| Teva Pharmaceuticals USA, INC. | $121.94 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.58 | 2023-2025 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $81.91 | 2025 | Cobenfy |
| Pfizer INC. | $51.23 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $46.56 | 2023-2024 | Yupelri |
| Lilly USA, LLC | $43.28 | 2023-2024 | Mounjaro, Trulicity, Zepbound |
| Exact Sciences Corporation | $33.54 | 2024-2025 | Cologuard Collection Kit |
| Indivior INC. | $31.91 | 2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $25.88 | 2025 | Spravato |
| Astellas Pharma US INC | $18.68 | 2025 | Veozah |
| Phadia US INC. | $18.46 | 2024 | Immunocap |
| Corium, LLC | $17.94 | 2023 | Azstarys |
| Braeburn INC. | $15.79 | 2024 | Brixadi |
| Cipher Pharmaceuticals US LLC | $14.27 | 2025 | Natroba, Spinosad |
| Amgen INC. | $13.68 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Brady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.